287 related articles for article (PubMed ID: 25600440)
1. Measurement of dabigatran plasma concentrations by calibrated thrombin clotting time in comparison to LC-MS/MS in human volunteers on dialysis.
Schmohl M; Gansser D; Moschetti V; Stangier J
Thromb Res; 2015 Mar; 135(3):532-6. PubMed ID: 25600440
[TBL] [Abstract][Full Text] [Related]
2. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate.
Douxfils J; Dogné JM; Mullier F; Chatelain B; Rönquist-Nii Y; Malmström RE; Hjemdahl P
Thromb Haemost; 2013 Sep; 110(3):543-9. PubMed ID: 23783171
[TBL] [Abstract][Full Text] [Related]
3. Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays.
Douxfils J; Lessire S; Dincq AS; Hjemdahl P; Rönquist-Nii Y; Pohanka A; Gourdin M; Chatelain B; Dogné JM; Mullier F
Thromb Haemost; 2015 Apr; 113(4):862-9. PubMed ID: 25519251
[TBL] [Abstract][Full Text] [Related]
4. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran.
Stangier J; Feuring M
Blood Coagul Fibrinolysis; 2012 Mar; 23(2):138-43. PubMed ID: 22227958
[TBL] [Abstract][Full Text] [Related]
5. From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples.
Helin TA; Lemponen M; Hjemdahl P; Rönquist-Nii Y; Lassila R; Joutsi-Korhonen L
Thromb Res; 2015 Jul; 136(1):154-60. PubMed ID: 25981140
[TBL] [Abstract][Full Text] [Related]
6. On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation.
Skeppholm M; Hjemdahl P; Antovic JP; Muhrbeck J; Eintrei J; Rönquist-Nii Y; Pohanka A; Beck O; Malmström RE
Thromb Res; 2014 Oct; 134(4):783-9. PubMed ID: 25172669
[TBL] [Abstract][Full Text] [Related]
7. Diluted thrombin time reliably measures low to intermediate plasma dabigatran concentrations.
Božič-Mijovski M; Malmström RE; Malovrh P; Antovic JP; Vene N; Šinigoj P; Mavri A
Ann Clin Biochem; 2016 Jul; 53(Pt 4):446-51. PubMed ID: 26392631
[TBL] [Abstract][Full Text] [Related]
8. Thrombelastography detects dabigatran at therapeutic concentrations in vitro to the same extent as gold-standard tests.
Solbeck S; Ostrowski SR; Stensballe J; Johansson PI
Int J Cardiol; 2016 Apr; 208():14-8. PubMed ID: 26826624
[TBL] [Abstract][Full Text] [Related]
9. Multianalyte Determination of NOACs Using LC-MS/MS and Comparison with Functional Coagulation Assays.
Slavik L; Lukes J; Friedecky D; Zhanelova M; Nemcova M; Ulehlova J; Prochazkova J; Hlusi A; Palova M; Vaclavik J
Clin Lab; 2018 Oct; 64(10):1611-1621. PubMed ID: 30336535
[TBL] [Abstract][Full Text] [Related]
10. Comparisons between diluted thrombin time, ecarin chromogenic assays, and UPLC-MS for plasma level dabigatran quantification: Results from DRIVING study.
de Fautereau-Vassel A; Mokhtarian A; Mangenot M; Krekounian O; Kousignian I; Delavenne X; Curis E; Gouin-Thibault I; Siguret V
Int J Lab Hematol; 2024 Feb; 46(1):120-127. PubMed ID: 37710085
[TBL] [Abstract][Full Text] [Related]
11. UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays.
Kuhn J; Gripp T; Flieder T; Dittrich M; Hendig D; Busse J; Knabbe C; Birschmann I
PLoS One; 2015; 10(12):e0145478. PubMed ID: 26699714
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma.
Antovic JP; Skeppholm M; Eintrei J; Boija EE; Söderblom L; Norberg EM; Onelöv L; Rönquist-Nii Y; Pohanka A; Beck O; Hjemdahl P; Malmström RE
Eur J Clin Pharmacol; 2013 Nov; 69(11):1875-81. PubMed ID: 23784008
[TBL] [Abstract][Full Text] [Related]
13. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples.
Hapgood G; Butler J; Malan E; Chunilal S; Tran H
Thromb Haemost; 2013 Aug; 110(2):308-15. PubMed ID: 23783268
[TBL] [Abstract][Full Text] [Related]
14. Determination of dabigatran in plasma, serum, and urine samples: comparison of six methods.
Du S; Weiss C; Christina G; Krämer S; Wehling M; Krämer R; Harenberg J
Clin Chem Lab Med; 2015 Jul; 53(8):1237-47. PubMed ID: 25720084
[TBL] [Abstract][Full Text] [Related]
15. Real life dabigatran and metabolite concentrations, focused on inter-patient variability and assay differences in patients with atrial fibrillation.
Boonen K; Schmitz E; Rozestraten F; van den Heuvel D; Brunsveld L; van der Voort P; van de Kerkhof D
Clin Chem Lab Med; 2017 Oct; 55(12):2002-2009. PubMed ID: 28328523
[TBL] [Abstract][Full Text] [Related]
16. The effect of dabigatran on thrombin generation and coagulation assays in rabbit and human plasma.
Zhang C; Zhang P; Li H; Han L; Zhang L; Zhang L; Yang X
Thromb Res; 2018 May; 165():38-43. PubMed ID: 29558660
[TBL] [Abstract][Full Text] [Related]
17. An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery.
Eriksson BI; Mikuska Z; Feuring M; Amiral J; Haertter S; Stangier J; Nehmiz G; Weitz JI
Thromb Res; 2016 Aug; 144():158-64. PubMed ID: 27352238
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Accuracy of a Novel Chromogenic Direct Thrombin Inhibitor Assay: Clinical Experiences for Dabigatran Monitoring.
Poli S; Härtig F; Spencer C; Ebner M; Birschmann I; Kuhn J; Faix S; Ziemann U; Häring HU; Lehmann R; Peter A; Hörber S
Thromb Haemost; 2017 Dec; 117(12):2369-2375. PubMed ID: 29212124
[TBL] [Abstract][Full Text] [Related]
19. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
Douxfils J; Mullier F; Robert S; Chatelain C; Chatelain B; Dogné JM
Thromb Haemost; 2012 May; 107(5):985-97. PubMed ID: 22438031
[TBL] [Abstract][Full Text] [Related]
20. Comparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START-Laboratory Register.
Cini M; Legnani C; Cosmi B; Testa S; Dellanoce C; Paoletti O; Marcucci R; Poli D; Paniccia R; Pengo V; Tripodi A; Palareti G;
Int J Lab Hematol; 2018 Apr; 40(2):229-236. PubMed ID: 29314632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
